0RNK Stock Chart & Stats
€4.80
€0.03(1.17%)
At close: 4:00 PM EST
€4.80
€0.03(1.17%)
Day’s Range― - ―
52-Week Range€2.90 - €6.19
Previous CloseN/A
Volume2.44K
Average Volume (3M)16.48K
Market Cap
€965.02M
Enterprise Value€722.43
Total Cash (Recent Filing)€230.87M
Total Debt (Recent Filing)€59.86M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Sep 25, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding236,280,200
10 Day Avg. Volume29,766
30 Day Avg. Volume16,477
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-25.87
Price to Sales (P/S)164.59
P/FCF Ratio-7.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.58Price Target Upside78.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.66
Revenue Forecast (FY)€6.03M
Bulls Say, Bears Say
Bulls Say
Phase III ExecutionCompleted enrollment in a large, well-powered Phase III trial reduces execution uncertainty and creates a defined clinical catalyst. Robust operational controls and the planned composite endpoint provide a credible foundation for assessing lanifibranor’s regulatory and commercial potential.
Cash RunwayThe cash position supports continued development through the planned Phase III readout and limits immediate dependence on capital markets. Potential warrant proceeds could extend runway further, giving management time to pursue data-driven partnering or financing decisions.
Lanifibranor Differentiation And Market OpportunityPrior efficacy signals, regulatory designations and a large underdiagnosed MASH population support meaningful long-term opportunity if Phase III confirms benefit. Lanifibranor’s metabolic and fibrosis-related effects may also help position it across clinically important patient groups.
Bears Say
No Approved Product RevenueInventiva remains a clinical-stage company without marketed products or recurring sales, leaving future economics dependent on successful development, licensing or partnerships. The sharp revenue decline and widened losses show that current operations do not yet provide a durable self-funding base.
Cash Burn And Negative EquityPersistent cash consumption and a negative capital base reduce financial flexibility and increase reliance on equity, warrants or collaboration proceeds. Even with substantial cash currently available, ongoing losses could require additional funding before commercial revenues emerge.
Clinical Safety And Competitive RiskRegulatory scrutiny of fluid retention, weight gain and cardiac risk could constrain labeling or adoption, while established and emerging competitors raise the efficacy bar. The investment case therefore remains highly dependent on a strong Phase III result and favorable risk-benefit profile.
Inventiva News
0RNK FAQ
What was Inventiva SA’s price range in the past 12 months?
Inventiva SA lowest share price was €2.90 and its highest was €6.19 in the past 12 months.
What is Inventiva SA’s market cap?
Inventiva SA’s market cap is €965.02M.
When is Inventiva SA’s upcoming earnings report date?
Inventiva SA’s upcoming earnings report date is Sep 25, 2026 which is in 28 days.
How were Inventiva SA’s earnings last quarter?
Inventiva SA released its earnings results on Mar 30, 2026. The company reported -€0.926 earnings per share for the quarter, missing the consensus estimate of -€0.237 by -€0.689.
Is Inventiva SA overvalued?
According to Wall Street analysts Inventiva SA’s price is currently Undervalued.
Does Inventiva SA pay dividends?
Inventiva SA pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on Inventiva SA dividends here
What is Inventiva SA’s EPS estimate?
Inventiva SA’s EPS estimate is -0.33.
How many shares outstanding does Inventiva SA have?
Inventiva SA has 236,280,200 shares outstanding.
What happened to Inventiva SA’s price movement after its last earnings report?
Inventiva SA reported an EPS of -€0.926 in its last earnings report, missing expectations of -€0.237. Following the earnings report the stock price went down -7.566%.
Which hedge fund is a major shareholder of Inventiva SA?
Currently, no hedge funds are holding shares in GB:0RNK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Inventiva SA
Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
0RNK Stock 12 Month Forecast
Average Price Target
€8.58
▲(78.83% Upside)